M-M-R® II

Product Information

• Name: M-M-R® II
• Type: Measles, mumps, and rubella virus vaccine, live, attenuated, Merck Std.
• Form: Single-dose vials, lyophilized powder for injection (0.5 mL/dose after reconstitution)
• Manufacturer: Merck Canada Inc.

Indications and Clinical Use

• Indication: Simultaneous vaccination against measles, mumps, and rubella in persons 12 months of age or older.
• Special Populations:
  • Infants less than 12 months may fail to respond to the measles component.
  • Infants vaccinated before 12 months should be revaccinated with two additional doses after reaching 12 months of age.
  • Vaccination is recommended for susceptible individuals in high-risk groups such as students at post-secondary institutions, health care workers, and military personnel.
  • Prior to international travel, susceptible individuals should receive M-M-R® II.

Contraindications

• Hypersensitivity to any component, including gelatin and neomycin.
• Pregnant women should not receive the vaccine, and pregnancy should be avoided for one month following vaccination.
• Individuals with severe febrile respiratory illness or other active febrile infection.
• Patients receiving immunosuppressive therapy or with primary/acquired immunodeficiency states.
• Individuals with active untreated tuberculosis.

Warnings and Precautions

• General: Do not give intravascularly; only subcutaneous administration.
• Severe Allergic Reactions: Anaphylaxis can occur; epinephrine should be available.
• Monitoring: Monitor individuals with a history of convulsions or cerebral injury.
• Immune Compromised Individuals: Vaccination may be less effective; monitor for vaccine-preventable diseases.
• Transmission: Theoretical risk of transmission of rubella virus; no confirmed evidence for measles or mumps.

Adverse Reactions

• Common: Injection site pain, fever, rash, headache, dizziness, irritability.
• Rare: Anaphylaxis, thrombocytopenia, febrile convulsions, encephalitis, Guillain-Barré syndrome, arthritis.

Drug Interactions

• Immune globulins can interfere with the immune response; defer vaccination for at least 3 months after administration of immune globulin.

Dosage and Administration

• Dose: 0.5 mL subcutaneous injection.
• Primary Vaccination: Two doses, first at 12-15 months and second at 4-6 years.
• Revaccination: Required for infants vaccinated before 12 months and for specific high-risk groups.
• Concurrent Administration: Can be given with other vaccines, but at different sites and using separate syringes.

Storage and Stability

• Store refrigerated at 2°C to 8°C. Protect from light. Use reconstituted vaccine within 8 hours if stored at 2°C to 8°C.

Clinical Trials and Efficacy

• Efficacy: High seroconversion rates with strong immune responses against measles, mumps, and rubella.
• Safety: Generally well-tolerated with mild to moderate adverse reactions; severe reactions are rare.